Publications by authors named "M Yalciner"
Purpose: Immunotherapy efficacy in elderly patients with comorbidities and poor performance status is not well understood. More knowledge on this topic is needed to identify subgroups that will benefit from immunotherapy. We aimed to evaluate the effect of comorbidity burden in patients receiving immunotherapy.
View Article and Find Full Text PDFArticle Synopsis
- Regorafenib is a medication for metastatic colorectal carcinoma (mCRC) that often has low efficacy and can cause adverse effects; researchers explored the impact of statin use in patients undergoing treatment.
- In a retrospective study of 105 mCRC patients treated with regorafenib, those on statins were found to have shorter progression-free survival (1.9 vs. 4.2 months) and overall survival (4.7 vs. 6.7 months) compared to non-users.
- The findings suggest that statin use may be linked to worse survival outcomes in mCRC patients receiving regorafenib, but further research is necessary to validate these observations.
Article Synopsis
- Malignant melanoma is a deadly skin cancer that is becoming more common globally, and while it primarily affects skin, it can also occur in other organs like the lungs.
- A specific case involved a mass in the right lung that was initially thought to be small cell lung cancer; however, it was eventually diagnosed as melanoma through a biopsy.
- The case illustrates the importance of thorough examinations since atypical melanoma presentations can easily be mistaken for other cancers, emphasizing the need for careful skin evaluations to ensure timely and accurate diagnosis.
Medical practitioners are increasingly using artificial intelligence (AI) chatbots for easier and faster access to information. To our knowledge, the accuracy and availability of AI-generated chemotherapy protocols has not yet been studied. Nine simulated cancer patient cases were designed and AI chatbots, ChatGPT version 3.
View Article and Find Full Text PDFCentral nervous system (CNS) metastases can be seen at a rate of 30% in advanced stages for patients with non-small cell lung cancer (NSCLC). Growing evidence indicates the predictive roles of driver gene mutations in the development of brain metastases (BM) in recent years, meaning that oncogene-driven NSCLC have a high incidence of BM at diagnosis. Today, 3rd generation targeted drugs with high intracranial efficacy, which can cross the blood-brain barrier, have made a positive contribution to survival for these patients with an increased propensity to BM.
View Article and Find Full Text PDF